Verily CMO Jessica Mega, IBM Watson Health general manager Deborah DiSanzo, Humana CEO Bruce Broussard and Oscar cofounder Mario Schlosser
Nobody really knows what’s going to happen next in healthcare right now. But in less than a month, Forbes will convene the top leaders from the pharmaceutical, insurance and hospital industries to start figuring out what’s next.
Among our guest list: the chief executives of drug giants Pfizer, Merck, Bristol-Myers Squibb, Allergan, Novartis and Eli Lilly; the bosses from biotechnology companies Gilead Sciences, Celgene and Regeneron Pharmaceuticals; insurance industry leaders including Humana CEO Bruce Broussard, Oscar Health’s Mario Schlosser and Scott Serota, from Blue Cross Blue Shield of America; and health technology leaders including Jessica Mega from Verily, Deborah DiSanzos from IBM Watson and DNA sequencing pioneer Craig Venter. Add to that biotech entrepreneuer Martine Rothblatt, and amazing tech demonstrations and patient stories, and a bunch more stuff I can’t fit into this paragraph.
Pfizer CEO Ian Read, Eli Lilly incoming CEO David Ricks, United Therapeutics founder Martine Rothblatt, Regeneron founder Leonard Schleifer
It’s going to be a very big 24 hours. The Summit, now in it fifth year, has always sold out and we’re ahead of our projections, but there is still space. You can see an agenda here, and ask for an invitation by emailing healthcare at forbes dot com.
One big discussion comes down to a single issue: value. Executives across the healthcare business are falling back on this word, but they don’t always seem to mean the same thing. Some are arguing that their products and services should be worth a lot of money; some mean that other companies’ products and services cost too much. Getting to a common definition will be a challenge.
The value question will be a big topic for billionaire Stefano Pessina, one of healthcare’s richest men, when he kicks off the meeting on the evening of November 30. Pessina has turned Walgreens and Boots, companies that are iconically American and British, into the only drug retail chain based in America that is truly international. What advantages come from that scale?
We’ll follow that up with an interview with Novartis chief executive Joseph Jimenez, who has been wrestling with these exact same issues. How can a large pharmaceutical company work with insurers so that its drugs are paid for? Jimenez has proposed innovative new pricing models, but his new heart failure drug, Entresto, has not been able to translate those into U.S. commercial success.
The morning of December 1 will start with a big discussion on drug prices. Brent Saunders, the chief executive of Allergan, has taken a stand that his company won’t take the big price increases. Steve Miller, the chief medical officer of Express Scripts, has been one of the biggest critics of pharma price increases. Together, they’ll try to come to some consensus.
Allergan CEO Brent Saunders,Express Scripts CMO Steve Miller, Celgene CEO Mark Alles, Bristol CEO Giovanni Caforio and Merck CEO Kenneth Frazier
A little later in the morning, we’ll have a discussion featuring Giovanni Caforio, Kenneth Frazier, and Mark Alles, the chief executives of Bristol, Merck, and Celgene, along with Arch Venture Partners’ Robert Nelsen, the top healthcare venture capitalist on Forbes’ Midas List, about the central problems in humanity’s battle with cancer: we’re inventing breakthroughs at an unprecedented pace, but they’re proving financially costly. Treating cancer could soon requiring multiple medicines that each cost more than $ 100,000 each. Can we afford these breakthroughs?
The day will end with an all-star assemblage from across the drug business about an issue that has plagued the pharmaceutical industry for the entire time I’ve covered it: its reputation. The industry creates medicines that save lives, yet is viewed by much of the public with distrust. Is that something that can change? We’ll discuss drug prices, but also how medicines can get to people who need them, including in the developing world.
That last panel will feature Ian Read, the chief executive of Pfizer; John Milligan, the chief executive of Gilead Sciences, the maker of Sovaldi; David Ricks, the incoming chief executive of Eli Lilly; Leonard Schleifer, the billionaire founder and chief executive of Regeneron Pharmaceuticals; and Jim Robinson, the president in charge of Astellas Americas, the arm of the Japanese drug giant dedicated to the U.S., Canada, and Latin America.
And that’s just a first taste; I’ve skipped over our exploration of the future of the insurance industry and the role of the entrepreneur. But this amazing day will rely on a smart audience that will ask smart questions, helping us press executives to think harder and make sure there is a real exchange of ideas. Do you want to be part of it? Send us a note.